Selecting the optimal design for drug discontinuation trials in a setting of advanced, life-limiting illness [2]

JAMA Internal Medicine

Volumn 175, Issue 10, 2015, Pages 1725-

  Mody, Purav ^a   Nguyen, Oanh Kieu ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATTRIBUTABLE RISK; CLINICAL TRIAL (TOPIC); DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; MEDICAL DECISION MAKING; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; FEMALE; MALE; NEOPLASM; PALLIATIVE THERAPY; PROCEDURES;

CARDIOVASCULAR DISEASES; COGNITION DISORDERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS; PALLIATIVE CARE;

EID: 84943575971     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.4000     Document Type: Letter

References (1)

1. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691-700.